U.S. markets open in 6 hours 12 minutes
  • S&P Futures

    3,851.00
    +41.75 (+1.10%)
     
  • Dow Futures

    31,220.00
    +308.00 (+1.00%)
     
  • Nasdaq Futures

    13,103.50
    +192.50 (+1.49%)
     
  • Russell 2000 Futures

    2,243.30
    +44.10 (+2.01%)
     
  • Crude Oil

    62.61
    +1.11 (+1.80%)
     
  • Gold

    1,750.50
    +21.70 (+1.26%)
     
  • Silver

    27.00
    +0.56 (+2.14%)
     
  • EUR/USD

    1.2070
    -0.0018 (-0.14%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3957
    +0.0035 (+0.25%)
     
  • USD/JPY

    106.6070
    +0.1050 (+0.10%)
     
  • BTC-USD

    46,609.18
    +2,078.72 (+4.67%)
     
  • CMC Crypto 200

    931.31
    -1.83 (-0.20%)
     
  • FTSE 100

    6,573.07
    +89.64 (+1.38%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Aptinyx to Present at Upcoming Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following virtual investor conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference at 3:00 p.m. ET on Monday, September 14, 2020; and

  • Cantor Virtual Global Healthcare Conference at 8:00 a.m. ET on Thursday, September 17, 2020.

A live webcast of each presentation will be available on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005303/en/

Contacts

Investor and Media Contact:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377